Immix Biopharma, Inc. IMMX Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s cash and cash equivalents, end of period?
- Immix Biopharma, Inc. (IMMX) reported cash and cash equivalents, end of period of $79.25M in Q1 2026.
- How has Immix Biopharma, Inc.'s cash and cash equivalents, end of period changed year-over-year?
- Immix Biopharma, Inc.'s cash and cash equivalents, end of period increased by 397.8% year-over-year, from $15.92M to $79.25M.
- What is the long-term trend for Immix Biopharma, Inc.'s cash and cash equivalents, end of period?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s cash and cash equivalents, end of period has grown at a 199.3% compound annual growth rate (CAGR), from $391.09K to $93.93M.